NASDAQ: BBCP INVESTOR PRESENTATION | March 2026 Disclaimer Forward-Looking Statements This investor presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "for ...

4Q 2025 INVESTOR PRESENTATION March 10, 2026 We make the American Dream of home possible. Partnering with homeowners throughout the lifecycle of the homeownership journey. Serving the Buyer First Time Homebuyer Veteran / Active Duty Move Up / Downsize Relocation Supporting the Purchase Servicing the Mortgage Optimizing the Journey Title Services Escrow/ Closing Homeowners Insurance Building Trust Continuing Customer Relationship Facilitate additional lending opportunities HELOC Closed-End Second Refinance S ...

Q4 and Full Year 2025 Results March 10, 2026 This presentation provides select highlights about Motorsport Games Inc.'s results of operations. Please see Motorsport Games' 2025 Form 10-K, filed with the SEC and Q4 and full year 2025 earnings release for more complete information on the Company's results of operations, cash flows, financial condition and liquidity. motorsportgames 1 Q4 2025 Highlights Financial Highlights Key Highlights – FY 2025 and Subsequent Update *Adjusted EBITDA is a non-GAAP financial ...

FY 2025 Investor Supplement LAST UPDATED 03.10.2026 © 2026 Finance of America Companies Disclaimer Forward Looking Statements This presentation includes forward-looking statements within the meaning of the "safe harbor" provisions of the United States of America (the "U.S.") Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events, many of which, by their ...

CONNECT WITH NATURE Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvement in gross profit and gross margin. All statements (o ...

Summary of Block (NYSE: SQ) Conference Call - March 10, 2026 Company Overview - **Company**: Block (NYSE: SQ) - **Key Products**: Square, Cash App, Square Financial Services Core Points and Arguments Company Transformation - Block has undergone significant changes over the past two years, transitioning from a rigid business unit structure to a more functionalized organization, allowing for better resource allocation and project prioritization [3][5][7] - The functionalization has enabled the development of the Neighborhoods product, which aims to connect local businesses and consumers [5][6] Financial Performance - In Q4 2025, Block reported a **24% growth in gross profit** and a **33% growth in Cash App gross profit** [8] - A **40% reduction in workforce** was implemented, driven by advancements in AI tools that have increased productivity and efficiency in software development [10][11][12] AI Integration - The integration of AI tools has fundamentally changed the development process, allowing for faster and more efficient coding, which has led to a restructuring of the organization [11][12][41] - The company believes that the number of employees is no longer directly correlated with output due to the efficiency gained from AI [18][19] Cash App Growth - Cash App has shown strong growth, with **non-Borrow Cash App growth accelerating to over 14%** [44] - The introduction of new features and products, such as Cash App Green and Afterpay, has contributed to this growth [50][66] Neighborhoods Product - The Neighborhoods initiative aims to provide small businesses with tools to drive incremental growth, allowing them to compete with larger companies [71][73] - Early results show promising engagement, with a **5%-10% attach rate** for new customers and a **75%-80% retention rate** for sellers participating in the program [74][79] Pricing Strategy - Block is continuously adjusting its pricing strategy across its platforms, including Cash App and Square, to optimize value for customers while maximizing business results [92][93] - Recent changes include increased fees for instant deposits and cross-border transactions, while also aiming to regain market leadership in Bitcoin transactions [94][88] Additional Important Insights - The company is focused on enhancing its product offerings and maintaining a strong growth trajectory, with expectations of moving faster in product development despite the workforce reduction [20][66] - Block is committed to building a financial operating system that integrates various financial services, aiming to capture a larger share of customers' wallets [67][68] - The company is optimistic about sustaining growth in Cash App and expanding its user base through strategic initiatives and product enhancements [44][56][60] This summary encapsulates the key points discussed during the Block conference call, highlighting the company's strategic direction, financial performance, and growth initiatives.

MannKind Conference Call Summary Company Overview - **Company**: MannKind Corporation (NasdaqGM: MNKD) - **Event**: 2026 Conference on March 10, 2026 - **Speakers**: Mike Castagna (CEO), Chris Prentiss (CFO) Core Strategic Focus - MannKind is transitioning from a single product (inhaled insulin) to a diversified company, with significant growth following the acquisition of scPharmaceuticals in Q4 2025 [3][4] - The company aims to exceed Wall Street's growth expectations with multiple FDA approvals and a Phase 2 trial kickoff planned for 2026 [4] Revenue Streams and Growth - MannKind's revenue is projected to diversify, with a current annual revenue of approximately $200 million [5] - The company will be the exclusive manufacturer for Tyvaso, which is expected to stabilize revenue streams [6] - In Q4, MannKind generated $33 million from royalty streams, $23 million from Furoscix, and $22 million from Afrezza, indicating a shift where MannKind's controlled revenue is expected to grow significantly [10] - The company anticipates double-digit growth in Tyvaso DPI royalties for the upcoming years [8] Product Launches and Market Opportunities - MannKind is focusing on the launch of Afrezza for pediatric patients and the Furoscix auto-injector, which are seen as key growth drivers [8][15] - The auto-injector is expected to address a significant market need, particularly in hospitals, where fluid overload leads to high hospitalization rates [14][15] - The company estimates a potential revenue of $110 million to $120 million for Furoscix in 2026, with the auto-injector expected to enhance this figure [15] Competitive Landscape - MannKind acknowledges the presence of competitors like Esperion Therapeutics but believes there is room for multiple players in the market [32] - The company is developing its own inhaled version of diuretics to meet market needs and enhance its product offerings [34] Afrezza and Pediatric Market - The shift from profitability to growth mode for Afrezza is driven by positive pediatric data and changes in treatment guidelines that position Afrezza alongside pumps and multiple daily injections [42] - The company is targeting a market share of 20-30% in the pediatric segment, which could translate to $300-$500 million in revenue [45] Pipeline Developments - MannKind is conducting a Phase 2 trial for inhaled nintedanib, with expectations of demonstrating improved tolerability and efficacy compared to oral formulations [46][58] - The company is optimistic about the potential of its inhaled therapies, which are designed to deliver localized treatment to the lungs [58] Financial Outlook - MannKind is positioned for a strong financial year, with a focus on investment in product launches while maintaining a neutral to positive cash flow [66] - The company has a solid balance sheet, having paid off a convertible debt and maintaining a term loan with Blackstone due in 2030 [66] Market Perception - There is a belief that the market undervalues MannKind, focusing too heavily on the royalty stream from Tyvaso while overlooking the company's growth potential and diverse product pipeline [70][72] - The management emphasizes the importance of demonstrating successful product launches to improve stock performance [72]

Novavax 2026 Conference Call Summary Company Overview - **Company**: Novavax (NasdaqGS: NVAX) - **Focus**: Transition from COVID vaccine development to innovative partnerships and business development leveraging its Matrix-M adjuvant technology and nanoparticle technology [1][3] Core Strategies and Developments - **Pivot in Strategy**: Novavax has shifted from solely focusing on COVID vaccine development to a broader strategy involving partnerships and out-licensing its technology [3][4] - **Partnerships**: Recent deals with Sanofi in 2024 and Pfizer in January 2026 highlight the company's strategy to leverage its technology for multiple vaccine candidates [4][11] - **Research and Development**: The R&D team is focused on three key areas: data generation, innovation in adjuvants, and developing new assets using nanoparticle technology [5][6] Key Technologies - **Matrix-M Technology**: This adjuvant technology is central to Novavax's strategy, showing potential in both vaccine and immunotherapy applications, particularly in oncology [9][24] - **Pipeline Candidates**: Novavax is developing vaccines for Clostridioides difficile, Varicella-Zoster Virus (VZV), and Respiratory Syncytial Virus (RSV), with potential clinical trials starting as early as 2027 [6][30] Financial Performance and Projections - **Financial Health**: The company has significantly reduced R&D and SG&A expenses by over $1 billion and current liabilities by $2 billion, positioning itself for potential non-GAAP profitability by 2028 [56][57] - **Revenue Streams**: The Pfizer deal includes a $30 million upfront payment and potential milestones of up to $500 million, along with royalties that could yield significant long-term revenue [20][21] Market Potential - **Vaccine Market Growth**: The global vaccine market is projected to exceed $60 billion by 2032, presenting substantial opportunities for Novavax's technology [27] - **Unlocking Value**: The technology's ability to enhance immune responses and reduce costs of goods is appealing to potential partners, particularly those facing challenges in their own pipelines [25][28] Upcoming Catalysts - **Partnership Announcements**: Continued execution of the partnership strategy with potential new deals expected [11][22] - **Advancements from Existing Partnerships**: Monitoring developments from partners like Sanofi and Pfizer, particularly regarding the launch of Nuvaxovid and combination vaccine programs [22][23] - **Pipeline Progress**: Data and innovations from Novavax's own R&D efforts will be critical to future growth [24] Intellectual Property and Competitive Position - **Patent Protection**: Novavax has existing or pending patent applications for Matrix-M that extend into the 2040s, providing a competitive edge in the vaccine market [43][51] Conclusion - **Future Outlook**: Novavax is optimistic about its position in the biotech landscape, focusing on value creation through partnerships and innovative technology, with a strong emphasis on collaboration and humility in its corporate culture [68]

Alignment Healthcare (NasdaqGS:ALHC) 2026 Conference March 10, 2026 03:40 PM ET Company ParticipantsJim Head - CFOJohn Kao - Founder and CEOWhit Mayo - Senior Managing DirectorWhit Mayofor coming in today, guys. We've got Jim Head, the new CFO, John Kao, CEO of Alignment. I'm happy to have you guys here today. Maybe just at a high level, John, you have been able to successfully sidestep a lot of the challenges presented to the industry in the last, you know, two years. I've called this the deep cleansing. Y ...

Summary of Aura Biosciences Conference Call Company Overview - Aura Biosciences is focused on developing a novel class of drugs known as virus-like drug conjugates (VDCs) specifically for ocular oncology, with a lead indication in early choroidal melanoma currently in phase 3 trials [3][4] - The company is also exploring opportunities in bladder cancer and other ocular oncology indications, marking a significant innovation in a field that has seen no advancements in 100 years [3][4] Core Points and Arguments Ocular Oncology - The VDCs are designed to target cancer cell membranes with a photosensitizer, activated by infrared light, leading to necrosis of cancer cells without cytotoxicity [8][9] - The dual mechanism of action not only directly targets cancer cells but also stimulates an immune response, potentially preventing metastasis and recurrence [11][12] - Early diagnosis of choroidal melanoma is feasible through imaging diagnostics, allowing for timely intervention [12][13] - The current standard of care, radiotherapy, poses a risk of blindness, creating a significant unmet need for vision-preserving therapies [12][13] Market Opportunity - The estimated patient population for early choroidal melanoma is around 8,000 in the U.S. and Europe, with only about 2,000 currently treated with radiotherapy [16][17] - The company anticipates that once a drug is approved, all patients classified as high-risk indeterminate lesions will be treated as early choroidal melanomas, significantly expanding the market [17] - The potential addressable market across various ocular oncology indications is approximately 66,000 patients, with specific estimates of 20,000 for metastasis to the choroid and 35,000 for cancers of the ocular surface [43][44] Clinical Development and Regulatory Strategy - The phase 3 study is designed to enroll patients with documented growth, ensuring a robust study design that aligns with regulatory expectations [23][25] - The company is optimistic about obtaining a broad label from the FDA, similar to precedents set by other drugs [25][26] - Top-line data from the phase 3 study is expected in Q4 of 2027, with enrollment anticipated to complete earlier than year-end [27][32] Bladder Cancer Program - The bladder cancer program shares similarities with the ocular oncology approach, focusing on early intervention to prevent recurrence [45] - Initial studies have shown promising results, with significant responses in intermediate-risk patients [51] - The company is exploring both neoadjuvant and immunoablative strategies, with a focus on enhancing immune responses through optimized treatment regimens [53][60] Other Important Content - The company emphasizes the importance of educating ocular oncologists and retina specialists about the new treatment options to facilitate timely referrals and interventions [19][20] - There is a strong focus on maintaining a high safety profile for the drug, which is crucial for gaining acceptance among physicians [20][21] - The potential for expanding the drug's use across various rare cancers in ocular oncology presents a unique opportunity for Aura Biosciences to dominate this niche market [41][42]